Atypical antipsychotics (Second generation) updated on 06-10-2025

Neonatal death (< 28 days of life)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18385
R77574		 Kananen - Quetiapine, 2023 Died during the first neonatal week during pregnancy (anytime or not specified) retrospective cohort unexposed (general population or NOS) Adjustment: No 3.93 [0.24;64.57] C 0/152   29/35,133 29 152
ref
S3851
R8205		 Ellfolk (Control exposed to FGA), 2019 Early neonatal death (0–6 days) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: Yes 0.28 [0.05;1.44]
excluded (control group) 		4/4,204   7/1,564 11 4,204
ref
S3818
R8142		 Ellfolk (Control unexposed), 2019 Early neonatal death (0–6 days) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.87 [0.20;3.75] 4/4,204   19/21,069 23 4,204
ref
S2294
R8231		 Vigod, 2015 Neonatal mortality <90 days during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: No Matched 1.50 [0.53;4.24] C 9/1,021   6/1,021 15 1,021
ref
Total 3 studies 1.38 [0.61;3.10] 67 5,377
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kananen - Quetiapine, 2023Kananen - Quetiapine, 2023 3.93[0.24; 64.57]291528%ROB confusion: criticalROB selection: unclearROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Ellfolk (Control unexposed), 2019Ellfolk, 2019 1 0.87[0.20; 3.75]234,20431%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: low Vigod, 2015Vigod, 2015 1.50[0.53; 4.24]151,02161%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 1.38[0.61; 3.10]675,3770.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Control unexposed;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.38[0.61; 3.10]675,3770%NAKananen - Quetiapine, 2023 Ellfolk (Control unexposed), 2019 Vigod, 2015 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.20[0.33; 4.41]524,3560%NAKananen - Quetiapine, 2023 Ellfolk (Control unexposed), 2019 2 unexposed, sickunexposed, sick 1.50[0.53; 4.24]151,021 -NAVigod, 2015 1 Tags Adjustment   - No  - No 1.69[0.64; 4.47]441,1730%NAKananen - Quetiapine, 2023 Vigod, 2015 2   - Yes  - Yes 0.87[0.20; 3.77]234,204 -NAEllfolk (Control unexposed), 2019 1 MatchedMatched 1.50[0.53; 4.24]151,021 -NAVigod, 2015 1 All studiesAll studies 1.38[0.61; 3.10]675,3770%NAKananen - Quetiapine, 2023 Ellfolk (Control unexposed), 2019 Vigod, 2015 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3851

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.20[0.33; 4.41]524,3560%NAKananen - Quetiapine, 2023 Ellfolk (Control unexposed), 2019 2 unexposed, sick controlsunexposed, sick controls 1.50[0.53; 4.24]151,021 -NAVigod, 2015 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.28[0.05; 1.50]114,204 -NAEllfolk (Control exposed to FGA), 2019 10.510.01.0